PharmaPoint: Dermatophytic Onychomycosis (DO) – US Drug Forecast and Market Analysis to 2022

Pages: 0 Published: June 01, 2013 Report Code: GDHC101PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • Listen
    Convert Text to Speech

Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.


Overview of DO, including epidemiology, etiology, general symptoms from infection, and disease management recommendations and guidelines.

Annualized DO market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO market.

Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically new therapies with novel routes of administration.

Analysis of the current and future market competition in the US DO market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

How big of an impact will topical agents have on the DO market? What do key opinion leaders think of this paradigm shift?

What new product is expected to become the market leader during the forecast period? How will this impact the existing generic therapies?

How will a change in the route of administration change the uptake of drugs in the US market?

What are the primary unmet needs that exist in the market according to key opinion leaders?

What alliance opportunities exist in this market for a company looking to tap into the DO market?

Key Players

Anacor Pharmaceuticals

Apricus Biosciences

Celtic Pharma Holdings


Palau Pharma

Topica Pharmaceuticals

Valeant Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Prognosis

3.1.4 Quality of Life

3.2 Symptoms

4 Epidemiology

4.1 Risk Factors and Comorbidities

4.1.1 Poor peripheral circulation is greater in older men

4.1.2 Household contact with other DO patients increases risk of infection

2.5 times

4.1.3 Immunosuppression increases susceptibility to DO infections

4.1.4 Prevalence of dermatophytic onychomycosis is higher in diabetics than in


4.2 Global Trends

4.3 Forecast Methodology

4.3.1 Sources Used

4.3.2 Forecast Assumptions and Methods

4.3.3 Sources Not Used

4.4 Epidemiology Forecast (2012–2022)

4.4.1 Prevalent Cases of Dermatophytic Onychomycosis

4.4.2 Age-Specific Prevalent Cases of Dermatophytic Onychomycosis

4.4.3 Sex-Specific Prevalent Cases of Dermatophytic Onychomycosis

4.5 Discussion

4.5.1 Epidemiological Trends

4.5.2 Limitations of the Analysis

4.5.3 Strengths of the Analysis

5 Disease Management

5.1 Treatment Overview

5.1.1 Diagnosis

5.1.2 Clinical Practice

6 Competitive Assessment

6.1 Overview

6.2 Strategic Competitor Assessment

6.3 Product Profiles

6.3.1 Terbinafine

6.3.2 Itraconazole

6.3.3 Fluconazole

6.3.4 Ketoconazole

6.3.5 Griseofulvin

6.3.6 Ciclopirox

7 Opportunity and Unmet Need

7.1 Overview

7.2 Unmet Needs

7.2.1 Unmet Need: Efficacious Oral and Topical Treatments

7.2.2 Unmet Need: Clinical Safety

7.2.3 Unmet Need: Patient Awareness

7.2.4 Unmet Need: Shorter Treatment Duration

7.2.5 Unmet Need: Higher Treatment Rates

7.2.6 Unmet Need: Prescribing Guidelines

7.2.7 Unmet Need: Differential Diagnosis

7.3 Unmet Needs Gap Analysis

7.4 Opportunities

7.4.1 Opportunity: Decreased Frequency of Dosing

7.4.2 Opportunity: Combinatorial Approaches to Treatment

8 Clinical Pipeline Assessment

8.1 Overview

8.2 Clinical Trials by Phase and Trial Status

8.3 Promising Drugs in Clinical Development

8.3.1 Efinaconazole

8.3.2 Tavaborole

8.3.3 TDT-067

8.3.4 Luliconazole

8.3.5 Albaconazole

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Valeant Pharmaceuticals International

9.3.2 Topica Pharmaceuticals

9.3.3 Anacor Pharmaceuticals

9.4 Late-Stage Competition

9.4.1 Celtic Pharmaceutical Holdings

9.4.2 Palau Pharma

9.5 Early-Stage Competition

9.5.1 Merck

9.5.2 Apricus Biosciences

10 Market Outlook

10.1 United States

10.1.1 Forecast

10.1.2 Key Events

10.1.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Diagnosed DO patients

11.4.2 Percent Drug-Treated Patients

11.4.3 Drugs Included in Each Therapeutic Class

11.4.4 Launch and Patent Expiry Dates

11.4.5 General Pricing Assumptions

11.4.6 Individual Drug Assumptions

11.4.7 Pricing of Pipeline Agents

11.5 Physicians and Specialists Included in this Study

11.6 About the Authors

11.6.1 Author

11.6.2 Reviewer

11.6.3 Epidemiologist

11.6.4 Global Head of Healthcare

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

List of Tables

Table 1: Symptoms of DO

Table 2: Risk Factors and Comorbidities for DO

Table 3: Sources of DO Prevalence Data

Table 4: Total Prevalent Cases of DO, Ages =15 Years, Men and Women, Selected Years, 2012–2022

Table 5: Total Prevalent Cases of DO, by Age, Men and Women, N = Millions (Row %), 2012

Table 6: Total Prevalent Cases of DO, by Sex, Ages = 15 Years, N=Millions, (Row %), 2012

Table 7: Treatment Guidelines for DO

Table 8: Most Prescribed Drugs for DO by Class in the US Market, 2012

Table 9: Leading Treatments for DO in the US, 2012

Table 10: Terbinafine SWOT Analysis, 2012

Table 11: United States Sales Forecasts ($m) for Terbinafine, 2012–2022

Table 12: Itraconazole SWOT Analysis, 2012

Table 13: United States Sales Forecasts ($m) for Itraconazole, 2012-2022

Table 14: Fluconazole SWOT Analysis, 2012

Table 15: United States Sales Forecasts ($m) for Fluconazole, 2012–2022

Table 16: Ketoconazole SWOT Analysis, 2012

Table 17: United States Sales Forecasts ($m) for Ketoconazole, 2012–2022

Table 18: Griseofulvin SWOT Analysis, 2012

Table 19: United States Sales Forecasts ($m) for Griseofulvin, 2012–2022

Table 20: Ciclopirox SWOT Analysis, 2012

Table 21: United States Sales Forecasts ($m) for Ciclopirox, 2012-2022

Table 22: Overall Unmet Needs – Current Level of Attainment

Table 23: Clinical Unmet Needs – Gap Analysis, 2012

Table 24: DO – Clinical Trials by Phase and Status in the US, 2012

Table 25: DO – Phase Pipeline, 2012

Table 26: Product Profile – Efinaconazole

Table 27: Efinaconazole SWOT Analysis, 2012

Table 28: United States Sales Forecasts ($m) for Efinaconazole, 2012–2022

Table 29: Product Profile – Tavaborole

Table 30: Tavaborole Phase III Clinical Efficacy Results

Table 31: Tavaborole SWOT Analysis, 2012

Table 32: United States Sales Forecasts ($m) for Tavaborole, 2012–2022

Table 33: Product Profile – TDT-067

Table 34: TDT-067 SWOT Analysis, 2012

Table 35: United States Sales Forecasts ($m) for TDT-067, 2012–2022

Table 36: Product Profile – Luliconazole

Table 37: Luliconazole SWOT Analysis, 2012

Table 38: United States Sales Forecasts ($m) for Luliconazole, 2012–2022

Table 39: Product Profile – Albaconazole

Table 40: Results of Phase IIb Multi-Arm Clinical Trial of Albaconazole

Table 41: Albaconazole SWOT Analysis, 2012

Table 42: United States Sales Forecasts ($m) for Albaconazole, 2012–2022

Table 43: Key Companies in the DO Market, 2012

Table 44: Valeant Pharmaceuticals International DO Therapy Portfolio Assessment, 2012

Table 45: Valeant Pharmaceuticals SWOT Analysis, 2012

Table 46: Topica Pharmaceuticals DO Therapy Portfolio Assessment, 2012

Table 47: Topica Pharmaceuticals SWOT Analysis, 2012

Table 48: Anacor Pharmaceuticals DO Therapy Portfolio Assessment, 2012

Table 49: Anacor Pharmaceuticals SWOT Analysis, 2012

Table 50: Sales Forecasts ($m) for DO in the United States, 2012–2022

Table 51: Key Events Impacting Sales for DO in the United States, 2012–2022

Table 52: United States DO Market – Drivers and Barriers, 2012–2022

Table 53: Key Launch Dates

List of Figures

Figure 1: Structure of Human Nail

Figure 2: Total Prevalent Cases of DO, Ages =15 Years, Men and Women, Selected Years, 2012–2022

Figure 3: Total Prevalent Cases of DO, by Age, Men and Women, N = Millions, 2012

Figure 4: Total Prevalent Cases of DO, by Sex, Ages = 15 Years, N = Millions, 2012

Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in DO , 2012–2022

Figure 6: Company Portfolio Gap Analysis in DO, 2012–2022

Figure 7: Sales for DO in the United States by Route of Administration, 2012–2022


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.